share_log

Chemomab Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-OrbiMed Israel BioFund GP Limited Partnership(19.7%),OrbiMed Israel GP Ltd.(19.7%)

Chemomab Therapeutics | SC 13D/A:超過5%持股股東披露文件(修正)-OrbiMed Israel BioFund GP Limited Partnership(19.7%),OrbiMed Israel GP Ltd.(19.7%)

美股sec公告 ·  2023/01/05 16:31
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息